Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAH vs VA in Newly Diagnosed Elderly AML
NCT07469046Phase 3Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of homoharringtonine in acute myeloid leukemia (AML) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Composite Complete Remission Rate at 8 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07469046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469046.